Edwards Lifesciences reported third quarter results showing global THV Sales grew 50% with EPS up 35 Percent (53 Percent Excluding Special Items). Fourth quarter sales and earnings guidance trimmed and still heavily reliant on Sapien uptake.
Boston Scientific’s new President and CEO has plenty to think about as the company’s third quarter sales performance shows some of its divisions struggling. Newly acquired technologies give cause for optimism however.
Stryker’s numbers look pretty solid compared with certain others. However a tough OUS sales environment, coupled with general downward pricing pressure especially in capital goods means the company has had to lower 2012 growth forecasts.
It’s not all doom and gloom for St.Jude, but its hard to find much good news from the revenue lines. AF is the shining star from the sales perspective, and the bottom line has been tarnished by inclusion of costs associated with reorganisation
J&J’s sales of $17.1Bn for the third quarter of 2012, represent an increase of 6.5% compared to Q3 2011. Synthes product sales contributed 5.8% to worldwide operational sales growth, net of the divestiture of the DePuy trauma business.
SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart, announced today that revenue and implants for the first nine months of 2012 have exceeded the company’s best 12-month totals to date.
PR Newswire (http://s.tt/1pMln)
Surgical Innovations has issued its 6 month financials which suggest the company has plenty of reasons to be cheerful as it looks forward to the fruits of new product approvals and distribution agreements in the U.S.
Stryker corporation is a big device player with orthopaedics, spine and neuro business to name three. Yet it’s European effort continues to result in falling share and disappointment. Recent management changes haven’t yet borne fruit, but the company is expecting better times ahead. While the medtech business can be a complicated affair, we suggest basic business principles still surely apply.
Before we saw the numbers we were backing the line that it would be stents up, pacing and spine down, and so it came to pass. Medtronic’s numbers show the importance of emerging markets and contributions from its newly acquired businesses as the company posts 5% revenue gains.
SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart, has announced revenue for the quarter ended June 30, 2012, marking the company’s best quarter to date and its fifth consecutive profitable quarter.
TranS1’s technology is intriguing enough to keep on capturing our attention, but its revenue and gross margin picture for Q2 2012 are not painting a picture of growth. Encouraging words from the boss though.
HeartWare International Inc. has announced revenue of $29.1 million for the second quarter ended June 30, 2012, representing a 42 percent increase from $20.4 million in revenue for the same period of 2011. However the company recorded a net loss more than double prior year as it invested in R&D and commercialisation activity.
Financial key performance indicators for S&N’s quarter, when set against the equivalent period a year ago show revenue of $1,029 million, up 2% on an underlying basis, trading profit of $234 million, up 6% on an underlying basis, with trading profit margin up 80 bps to 22.7% as Advanced Surgical Devices (ASD) division restructuring benefits come through
Georgia’s Mimedx Group is a developer of biomaterial solutions for surgical repair of soft tissues using human amniotic membrane. Pretty specialised field and never likely to be sponsoring the Olympics, but nonetheless the company’s recently stated Q2 financials suggest it’s in good shape, having grown consistently and turned red numbers black in the past twelve months.
Edwards Lifesciences Corporation has released its second quarter financial results which are, on face value, bucking the trend by showing sales growth of almost 16% (albeit excluding currency impact) to $482m compared with the equivalent period last year. Closer examination reveals that growth is almost exclusively related to the company’s Sapien transcatheter heart valve, launched in U.S and seeing continued growth internationally.
Baxter International Inc. has announced financial results for the second quarter and confirmed its full-year 2012 financial outlook. Sales increase of 4% year-on-year coupled with 1% income hike is in line with previous guidance.